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Letters to the Editor
Sir,
Pindolol in the treatment of complicated myocardial
infarction
In a letter to the Editor, Baber and Lewis!1! question
the suggestion made in our study!2) that oral pro-
phylactic treatment with beta-adrenoceptor block-
ing drugs should not start too early after the
infarction. They point to the results of the Hansteen
study!3! with propranolol, performed in high-risk
patients comparable to those in the pindolol study
and mention other studies where the reduction in
mortality was higher in patients who entered the
study 5-9 days ('early') after the infarction than in
those who entered the study later.
The results of the pindolol study, however,
suggest that the treated patients who entered the
study up to 5 days after the infarction fared worse
than those who were admitted later. To our know-
ledge, in none of the studies with a statistically
significant reduction in total mortality was treat-
ment begun earlier than 5 days after the infarction.
There is obviously confusion about the use of the
term 'early', because in the pindolol paper it refers
to the time up to the fifth day after the infarction
while Baber and Lewis in their letter call 'early' the
time from the fifth day onwards.
In addition, Lewis stated in a previous paper!4!
that the difference between pooled 'early' (up to
48 h) and late entry studies showed for the early
entry studies 'a small positive effect, but this had no
statistical or clinical significance' contrary to the
'highly significant effect of beta-blockade on total
mortality' in the pooled analysis of seven late-entry
trials.
Our data shows a similar tendency and are there-
fore well in accordance with Dr Lewis' previous
analysis.
We agree, however, with the suggestion that
patient groups with different benefit from the
treatment may have been entered at different time
points in different studies.
The possibility that the time of entry may not be
the only decisive factor for the outcome of the study
has been discussed in our paper on p. 374.
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Sir,
Pindolol in the treatment of complicated myocardial
infarction
In a letter to the Editor, Dr Prescott!'! criticizes
our using a discriminant analysis allowing for the
exclusion of main effects while keeping interactions
with these main effects in the model. Moreover, he
states that 'an occasional significant finding should
not cause great surprise'. On pages 368 and 369 of
our paper!2! ('Statistical analysis'), we have stated
explicitly that this discriminant analysis was
executed in the exploratory sense only — as well as
all other analyses reported except the analysis of the
null-hypothesis of equal treatment effects on sur-
vival under the intention-to-treat principle. The
latter analysis was performed as a confirmatory
one, using adjusted alpha-levels according to
Bonferroni-Holml3! and was the only one upon
which to base decisions about the effect of pindolol
on survival.
Exploratory data analysis is gaining increased
attention in the statistical and medical literature.
For the concepts of exploratory/confirmatory data
analysis see also W and PI. The exploratory dis-
criminant analysis was applied in the backward
stepwise manner, to show variables which possibly
may have a joint effect on total cardiac mortality.
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This method considers the effect of any variable
additional to that of those variables which are still
in the model and excludes the less important one
of any two highly correlated variables. Therefore,
such a discriminant analysis will yield the most
economic significant model' consisting of the
smallest possible number of variables to classify
patients as alive or dead. It was preferred to the
analysis of many unconnected contingency tables
(variable v. alive/dead), which method, exploratory
also, would not have considered the correlation
between the variables.
Any stepwise procedure such as the discriminant
analysis performed is per se exploratory in nature
since decisions about retaining or excluding vari-
ables in the model are data-dependent. Accord-
ingly, in a confirmatory approach (aiming at P
values to base decisions upon) stepwise procedures
would have no place, and naturally, the confirm-
atory analysis model would have to include the
main effects which generated the interactions also
contained in the model.
The fact that a variable shows up as being 'sig-
nificant' in an exploratory analysis means that in
future studies this variable should cause special
interest and further investigation.
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